By
Drug Target Review2024-05-08T15:00:42
Researchers showed that ESI1, or similar compounds, may help to slow or even reverse cognitive losses that can occur during aging.
Already a member? Sign in
By highlighting cutting-edge research and its practical applications, Drug Target Review enables readers to make decisions that accelerate innovation, translate discoveries into therapies, and create tangible benefits for patients worldwide.
By becoming a member you join a connected and collaborative community driving the industry forward. Member benefits include:
2026-07-10T09:00:00Z
2026-07-10T06:15:00Z
Contributor Professor Donald E Ingber, By Drug Target Review
2026-07-09T12:00:00Z
2026-07-07T12:00:00Z
2023-07-03T10:28:23
Sponsored by Merck
2023-06-20T12:34:32
Sponsored by NanoTemper Technologies
2026-05-05T13:24:00
Sponsored by HUB Organoids
2023-09-06T16:55:04
Sponsored by NanoTemper Technologies
2026-07-10T06:15:00
Contributor Professor Donald E Ingber, By Drug Target Review
2023-05-23T11:10:47
Sponsored by NanoTemper Technologies
Site powered by Webvision Cloud